Key regions: Australia, Italy, France, South Korea, Brazil
The demand for vaccines in CIS has been increasing steadily over the past few years.
Customer preferences: Customers in CIS have been increasingly aware of the importance of vaccines in preventing diseases and maintaining good health. This has led to a rise in demand for vaccines across the region. Additionally, the COVID-19 pandemic has further highlighted the importance of vaccines in preventing the spread of infectious diseases.
Trends in the market: The vaccines market in CIS has been witnessing a trend towards the development of new and innovative vaccines. This has been driven by the need to address emerging infectious diseases and to improve the efficacy and safety of existing vaccines. The market has also been witnessing a trend towards the adoption of combination vaccines, which offer protection against multiple diseases in a single shot.
Local special circumstances: One of the key challenges in the vaccines market in CIS is the lack of awareness and education about vaccines in some parts of the region. This has led to lower vaccination rates in certain areas, which in turn has contributed to the spread of vaccine-preventable diseases. Additionally, there are some logistical challenges in distributing vaccines to remote and rural areas, which can make it difficult to reach all segments of the population.
Underlying macroeconomic factors: The vaccines market in CIS is influenced by a range of macroeconomic factors, including government policies, healthcare infrastructure, and funding for research and development. The region has been investing in the development of its healthcare infrastructure, which has helped to improve access to vaccines. Additionally, there has been an increase in funding for research and development in the region, which has led to the development of new and innovative vaccines. However, the market is also subject to geopolitical risks, which can impact the availability and pricing of vaccines.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
